CE1226
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Alpha1 Antitrypsin Deficiency
Conditions
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
Trial Timeline
Apr 15, 2026 → Sep 15, 2033
NCT ID
NCT07326592About CE1226
CE1226 is a approved stage product being developed by CSL for Alpha1 Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07326592. Target conditions include Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema.
What happened to similar drugs?
1 of 1 similar drugs in Alpha1 Antitrypsin Deficiency were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07326592 | Approved | Recruiting |
Competing Products
6 competing products in Alpha1 Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-864 + Placebo | Vertex Pharmaceuticals | Phase 2 | 35 |
| Alpha1-proteinase inhibitor | CSL | Approved | 43 |
| Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) | Grifols | Phase 1/2 | 29 |
| Alpha-1 MP | Grifols | Phase 1/2 | 29 |
| Alpha-1 MP | Grifols | Phase 1/2 | 29 |
| ZF874 + Placebo | Centessa Pharmaceuticals | Phase 1 | 18 |